SA News • Jun. 18, 2012
From other sites
at MarketWatch.com (Aug 2, 2012)
at MarketWatch.com (Jun 14, 2011)
There are no Focus articles on KV.B.
There are no Transcripts on KV.B.
Jun. 18, 2012, 9:57 AMThe FDA says its analysis of compounded versions of the active ingredient in K-V Pharmaceuticals’ (KV.A -16.2%) Makena premature-birth prevention drug did not identify any major safety problems, but the agency reiterates that approved drugs are generally safer and more effective than compounded products. | Comment!
Oct. 13, 2011, 1:21 PMK-V Pharmaceutical (KV.A +22%) soars following a brief halt after it says information from two distinguished medical research bodies confirm that its FDA-approved Makena and unapproved compounded 17P formulations are not identical. The update clears previous concerns that were used by insurers to deny coverage for Makena prescriptions. | Comment!
We currently have no instablog posts on this stock.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
Other News & PR